Form 4: Syra Health Corp Director Ketan Paranjape Reports Stock Option Grant

Director Ketan Paranjape of Syra Health Corp. reported the acquisition of 15,170 stock options on January 7, 2025.

Summary

• Ketan Paranjape, a director at Syra Health Corp., has reported a transaction involving stock options.
• On January 7, 2025, Paranjape acquired 15,170 stock options with an exercise price of $0.7386.
• These options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• 25% of the options vested immediately upon grant, and the remaining options will vest in 12 equal monthly installments.
• Following this transaction, Paranjape beneficially owns 34,473 derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of a stock option grant, which is generally neutral to positive. It indicates that the director's interests are aligned with the company's long-term success.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is a routine disclosure for company insiders who have transacted in the company's securities. It is common for companies to grant stock options to directors as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the healthcare and technology sectors.
• The vesting schedule of 25% immediately and the remainder over 12 months is a fairly standard practice.
• Companies like Teladoc Health and Livongo Health also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging actions that increase shareholder value.

Key Dates

Keywords

stock options, equity incentive plan, director, beneficial ownership, Syra Health Corp, insider trading, form 4